Poole and colleagues examine molecular mimicry between Epstein-Barr virus (EBV) and self-antigens in systemic lupus erythematosus (SLE), establishing that similar mechanisms potentially operative in MS likely contribute to this related autoimmune disease. SLE represents a complex systemic autoimmune disease with multifactorial causation involving genetic predisposition, hormonal influences, and environmental triggers including infections. The research demonstrates that the pattern of autoantibody development in SLE is consistent with initiation through molecular mimicry, as initial autoantigenic epitopes encountered are limited in number and show cross-reactivity with viral proteins including EBV antigens. Subsequent autoantibody diversification through B-cell epitope spreading then broadens the autoimmune attack to additional self-antigens beyond those initially triggered by viral mimicry. EBV emerges as an excellent candidate for driving molecular mimicry in SLE based on strong serological and DNA-based evidence associating EBV infection with lupus development.
The research reveals that the sequence of autoimmune responses in SLE follows patterns expected from molecular mimicry initiation: limited initial autoantigenic specificity cross-reactive with viral proteins, followed by broadening to multiple self-antigens through epitope spreading. This progression suggests that initial EBV infection activates B cells recognizing cross-reactive epitopes on both viral and self-proteins, and subsequent expansion and differentiation of these B cells leads to diversified autoantibody responses against multiple self-antigens. The molecular mimicry mechanism explained by initial EBV-triggered cross-reactivity evolving to broader autoimmunity provides mechanistic understanding of how infectious triggers can initiate multifaceted autoimmune diseases. The evidence for EBV involvement in SLE establishes this virus as a particularly important environmental trigger for autoimmunity, consistent with findings in MS and other autoimmune conditions.
For MS patients, this research on molecular mimicry in SLE provides important insights applicable to MS pathogenesis, as similar mechanisms likely operate in both diseases. The research demonstrates how initial viral infection through molecular mimicry can initiate autoimmune responses that subsequently diversify and perpetuate independent of the triggering virus. MS patients should understand that their disease likely resulted from combination of EBV infection (or other herpesvirus infection) and molecular mimicry with myelin antigens, followed by broadening of the autoimmune attack through epitope spreading. This mechanistic understanding suggests that MS management might benefit from strategies controlling EBV replication and supporting antiviral immunity to prevent ongoing viral-triggered immune activation. Patients should also recognize that even if specific triggering infections occurred years in the past, ongoing immune activation against EBV or other persistent viruses might perpetuate MS disease progression, suggesting value in maintaining strong antiviral immunity throughout disease course.
